Shanghai Henlius Biotech

Quick facts

Marketed products

• Darzalex · Oncology
• POHERDY · Other

Phase 3 pipeline

• carboplatin and nab paclitaxel · Oncology
  This combination uses carboplatin to cross-link DNA and nab-paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.
• carboplatin/cisplatin-etoposide · Oncology
  Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death.
• EU-Perjeta® · Oncology
  EU-Perjeta is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER family receptors, inhibiting tumor cell growth signaling.
• EU-sourced Keytruda® · Oncology
  Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• EU-sourced YERVOY® · Oncology
  YERVOY (ipilimumab) blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
• HLX02 · Oncology
  HLX02 is a monoclonal antibody that binds to and blocks the PD-1 checkpoint receptor on immune cells, allowing them to recognize and attack cancer cells.
• HLX03 · Oncology
  HLX03 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX04 · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• HLX04, a bevacizumab biosimilar · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• HLX04-O · Oncology
  HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• HLX10 · Oncology
  HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX10, an engineered anti-PD-1 antibody · Oncology
  HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells.
• HLX11 · Oncology
  HLX11 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX13 · Oncology
  HLX13 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX14 · Oncology
  HLX14 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
• HLX15-IV · Oncology
  HLX15-IV is a humanized monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX17 · Oncology
  HLX17 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX22 · Oncology
  HLX22 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• US-sourced Keytruda®
  Keytruda is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.
• US-sourced YERVOY® · Oncology
  YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.

Phase 2 pipeline

• Cetuximab Injection [Erbitux] · Oncology
  Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing cancer cell growth and proliferation.
• HLX07
• HLX208 · Oncology
  HLX208 is a monoclonal antibody targeting PD-1.
• HLX26
• HLX43 Dose 1;
• HLX43 DOSE 1 IN ≥2L TNBC
• HLX43 DOSE1 IN 1L TNBC
• TCbHP

Phase 1 pipeline

• [14C]HLX208
• CN-Avastin®
• CN-Erbitux®
• CN-Prolia®
• CN-sourced DARZALEX®
• CN-sourced ipilimumab
• EU-Erbitux®
• EU-sourced DARZALEX®
• EU-sourced ipilimumab group
• HLX 208
• HLX05
• HLX15
• HLX15-SC-Rd
• HLX20
• HLX301
• HLX35
• HLX37
• HLX3901
• HLX42
• HLX48
• HLX51
• HLX53
• HLX60
• HLX60 combined with HLX10
• HLX97
• US-Avastin®
• US-DARZALEX FASPRO®-Rd
• US-Erbitux®
• US-sourced DARZALEX®
• US-sourced ipilimumab group

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Henlius Biotech portfolio CI brief
• Shanghai Henlius Biotech pipeline updates RSS